Dae-Won Kim

Dae-Won Kim

Auto-generated profile, based on publicly available information

Dae-Won Kim

Department of Internal Medicine Division of Cardiology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea Daejeon Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Journal of the American Heart Association
Verified
Journal Article
Closed access
KLKyusup Lee
Kyusup Lee
SHSeungbong Han
Seungbong Han
MLMyunhee Lee
Myunhee Lee
DKDae‐Won Kim
Dae‐Won Kim
JKJongbum Kwon
Jongbum Kwon
MPMahn-Won Park
Mahn-Won Park
Background: The secondary prevention with pharmacologic therapy is essential for preventing recurrent cardiovascular events in patients experiencing acute myocardial infarction. Guideline‐based optimal medical therapy (OMT) for patients with acute myocardial infarction consists of antiplatelet therapy, angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers, β‐blockers, and statins. We aimed to determine the prescription rate of OMT use at discharge and to evaluate the impact of OMT on long‐term clinical outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention in the drug‐eluting stent era using nationwide cohort data. Methods and Results: Using the National Health Insurance claims data in South Korea, patients with acute myocardial infarction who had undergone percutaneous coronary intervention with a drug‐eluting stent between July 2013 and June 2017 were enrolled. A total of 35 972 patients were classified into the OMT and non‐OMT groups according to the post–percutaneous coronary intervention discharge medication. The primary end point was all‐cause death, and the 2 groups were compared using a propensity‐score matching analysis. Fifty‐seven percent of patients were prescribed OMT at discharge. During the follow‐up period (median, 2.0 years [interquartile range, 1.1–3.2 years]), OMT was associated with a significant reduction in the all‐cause mortality (adjusted hazard ratio [aHR], 0.82 [95% CI, 0.76–0.90]; P <0.001) and composite outcome of death or coronary revascularization (aHR, 0.89 [95% CI, 0.85–0.93]; P <0.001). Conclusions: OMT was prescribed at suboptimal rates in South Korea. However, our nationwide cohort study showed that OMT has a benefit for long‐term clinical outcomes on all‐cause mortality and composite outcome of death or coronary revascularization after percutaneous coronary intervention in the drug‐eluting stent era.

2 June 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMyunhee Lee
Myunhee Lee
YHYu Ah Hong
Yu Ah Hong
JMJun-Pyo Myong
Jun-Pyo Myong
KLKyusup Lee
Kyusup Lee
MPMahn-Won Park
Mahn-Won Park
DKDae-Won Kim
Dae-Won Kim
Background: Although statins are an effective strategy for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in the general population, the benefits for dialysis patients are controversial. We sought to assess trends of statin use and evaluate outcomes of statin therapy in dialysis patients with different types of ASCVD. Methods: This nationwide retrospective population-based cohort study using data from the Korean National Health Insurance Service included adult patients (aged ≥ 18 years) undergoing chronic dialysis who had an initial ASCVD event in the time period of 2013 to 2018. Annual trends of statin use according to age, sex, and ASCVD types were analyzed. The association between 1-year mortality and statin use was examined using multivariable Cox proportional hazards regression analyses. Results: Among 17,242 subjects, 9,611(55.7%) patients were statin users. The overall prevalence of statin use increased from 52.9% in 2013 to 57.7% in 2018; the majority (77%) of dialysis patients were prescribed moderate-intensity statins. The proportions of low- or moderate-intensity statin use were similar, but high-intensity statin use increased from 5.7% in 2013 to 10.5% in 2018. The use of the statin/ezetimibe combination has gradually increased since 2016. Statin use was independently associated with the reduced 1-year all-cause mortality after adjusting for confounding factors (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.80–0.96, P = 0.004). Conclusion: The prevalence of statin prescriptions in dialysis patients after ASCVD event increased from 2013 to 2018. Most patients received moderate-intensity statin. However, high-intensity statin and statin/ezetimibe combination therapy has remarkably increased. Statin use was associated with decreased 1-year all-cause mortality in dialysis patients with ASCVD.

13 October 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMyunhee Lee
Myunhee Lee
DKDae-Won Kim
Dae-Won Kim
MPMahn-Won Park
Mahn-Won Park
KLKyusup Lee
Kyusup Lee
SHSung-Ho Her
Sung-Ho Her
OIon behalf of KAMIR-NIH registry investigators
on behalf of KAMIR-NIH registry investigators
Background: A substantial number of patients presenting with non-ST-elevation myocardial infarction (NSTEMI) and multivessel disease (MVD) have severe left ventricular systolic dysfunction (LVSD) (left ventricular ejection fraction (LVEF) less than 35%). But data are lacking regarding optimal percutaneous coronary intervention (PCI) strategy for these patients. The aim of this study was to compare the long-term outcomes of IRA (infarct-related artery)-only and multivessel PCI in patients with NSTEMI and MVD complicated by severe LVSD.Methods: Among 13,104 patients enrolled in the PCI registry from November 2011 to December 2015, patients with NSTEMI and MVD with severe LVSD who underwent successful PCI were screened. The primary outcome was 3-year major adverse cardiovascular events (MACEs), defined as all-cause death, any myocardial infarction, stroke, and any revascularization.Results: Overall, 228 patients were treated with IRA-only PCI (n = 104) or MV-PCI (n = 124). The MACE risk was significantly lower in the MV-PCI group than in the IRA-only PCI group (35.5% vs. 54.8%; hazard ratio [HR] 0.561; 95% confidence interval [CI] 0.378–0.832; p = 0.04). This result was mainly driven by a significantly lower risk of all-cause death (23.4% vs. 41.4%; hazard ratio [HR] 0.503; 95% confidence interval [CI] 0.314–0.806; p = 0.004). The results were consistent after multivariate regression, propensity-score matching, and inverse probability weighting to adjust for baseline differences.Conclusions: Among patients with NSTEMI and MVD complicated with severe LVSD, multivessel PCI was associated with a significantly lower MACE risk. The findings may provide valuable information to physicians who are involved in decision-making for these patients.

1 August 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
MLMyunhee Lee
Myunhee Lee
KLKyusup Lee
Kyusup Lee
DKDae‐Won Kim
Dae‐Won Kim
JCJung Sun Cho
Jung Sun Cho
TKTae‐Seok Kim
Tae‐Seok Kim
MPMahn-Won Park
Mahn-Won Park
Background: The benefits of long‐term maintenance beta‐blocker (BB) therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) have not been well established. Methods and Results: Using the Korean nationwide registry, a total of 7159 patients with AMI treated with PCI who received BBs at discharge and were free from death or cardiovascular events for 3 months after PCI were included in the analysis. Patients were divided into 4 groups according to BB maintenance duration: <12 months, 12 to <24 months, 24 to <36 months, and ≥36 months. The primary outcome was the composite of all‐cause death, recurrent MI, heart failure, or hospitalization for unstable angina. During a mean 5.0±2.8 years of follow‐up, over half of patients with AMI (52.5%) continued BB therapy beyond 3 years following PCI. After propensity score matching and propensity score marginal mean weighting through stratification, a stepwise inverse correlation was noted between BB duration and risk of the primary outcome (<12 months: hazard ratio [HR], 2.19 [95% CI, 1.95–2.46]; 12 to <24 months: HR, 2.10 [95% CI, 1.81–2.43];, and 24 to <36 months: HR, 1.68 [95%CI, 1.45–1.94]; reference: ≥36 months). In a 3‐year landmark analysis, BB use for <36 months was associated with an increased risk of the primary outcome (adjusted HR, 1.59 [95% CI, 1.37–1.85]) compared with BB use for ≥36 months. Conclusions: Among stabilized patients with AMI following PCI, longer maintenance BB therapy, especially for >36 months, was associated with better clinical outcomes. These findings might imply that a better prognosis can be expected if patients with AMI maintain BB therapy for ≥36 months after PCI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02806102.

1 July 2026 in Biointerphases
Verified
Journal Article
Open access
JLJuo Lee
Juo Lee
JLJae Woon Lim
Jae Woon Lim
HSHoon Seonwoo
Hoon Seonwoo
HKHaeYong Kweon
HaeYong Kweon
YJYou Young Jo
You Young Jo
DKDae-Won Kim
Dae-Won Kim
Polycaprolactone (PCL) has emerged as a promising biomaterial for artificial heart applications due to its biodegradability and mechanical properties. However, its hydrophobic nature and limited biocompatibility pose challenges for cardiovascular applications, requiring optimal cell-material interactions. This study investigates the surface modification of silk fibroin-derived peptide/PCL coatings to enhance biocompatibility and cellular response for potential artificial heart applications. PCL substrates were blended with varying concentrations of silk fibroin-derived peptide (0.2%, 0.5%, and 1% w/v). Surface characterization was performed using water contact angle measurements, Fourier transform infrared spectroscopy (FTIR), and scanning electron microscopy. Biocompatibility was evaluated through cell viability assays and CD31 expression analysis. Silk fibroin-derived peptide incorporation significantly improved surface hydrophilicity, with contact angles decreasing from 78° (bare PCL) to 62° (1% silk fibroin-derived peptide). FTIR analysis confirmed successful incorporation of silk fibroin-derived peptides, showing characteristic PCL ester C=O absorption at ∼1720 cm−1 and concentration-dependent amide I contributions at ∼1630–1670 cm−1. Cell viability studies demonstrated enhanced cellular response with increasing silk fibroin-derived peptide concentration, particularly evident at day 7. CD31 expression analysis revealed improved endothelial marker expression, with the highest levels observed on 1% silk fibroin-derived peptide-incorporated substrates. The results demonstrate that silk fibroin blended to PCL significantly enhances biocompatibility through improved hydrophilicity and cellular interactions. Taken together, these preliminary results indicate that silk fibroin-derived peptide-incorporated PCL could represent a promising biomaterial platform for artificial heart applications, with the potential to improve endothelial compatibility and support endothelialization.

11 September 2026 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
ECEun Ho Choo
Eun Ho Choo
ICIk Jun Choi
Ik Jun Choi
SLSungmin Lim
Sungmin Lim
DMDonggyu Moon
Donggyu Moon
DKDae‐Won Kim
Dae‐Won Kim
KCKiyuk Chang
Kiyuk Chang
Background: Fractional flow reserve (FFR) is established to guide revascularization in stable coronary disease and non‐culprit lesions in acute coronary syndromes (ACS). However, real‐world adherence to FFR guidance across the spectrum of ACS presentations, including ambiguous culprit scenarios, remains incompletely characterized. Aims: To evaluate the clinical impact of adherence to FFR guidance in ACS. Methods: From a multicenter prospective FFR registry, we analyzed 501 ACS patients who underwent FFR measurement: 222 with clear culprit lesions and 279 with ambiguous culprit lesions. Patients were classified as FFR‐concordant (all FFR ≤ 0.80 treated; all FFR > 0.80 deferred) or FFR‐discordant (≥ 1 FFR‐hemodynamic mismatch). The patient‐oriented composite endpoint (POCE) comprised all‐cause death, myocardial infarction, or any revascularization; the patient‐oriented FFR‐related composite endpoint (POFRC) comprised cardiac death or myocardial infarction or revascularization involving an FFR‐assessed vessel at 2 years. Results: Among 501 patients, 431 (86%) received FFR‐concordant management and 70 (14%) FFR‐discordant management. FFR discordance clustered in the gray zone (0.75–0.85), with 3.5‐fold higher prevalence compared with other FFR ranges. Over 2 years, FFR‐discordant management was associated with significantly higher POCE (Kaplan−Meier incidence 20.0% vs. 10.4%; propensity‐weighted hazard ratio [HR] 2.33, 95% confidence interval [CI] 1.27–4.29, p = 0.009). The POFRC confirmed and strengthened this association (19.0% vs. 8.8%; propensity‐weighted HR 2.59, 95% CI 1.37–4.91, p = 0.004). The adverse impact of FFR discordance was consistent across clear culprit and ambiguous culprit subgroups ( p for interaction = 0.52) and across types of ACS ( p for interaction = 0.91). Conclusions: In real‐world ACS management, adherence to FFR guidance is associated with superior clinical outcomes compared with FFR‐discordant decision‐making.